Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REVONTO vs CYCLOBENZAPRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Induction and maintenance of procedural sedation,General anesthesia induction and maintenance
Treatment of muscle spasm associated with acute, painful musculoskeletal conditions (FDA approved),Adjunct to rest and physical therapy for relief of muscle spasm (FDA approved)
4 mg orally twice daily, with or without food.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Terminal elimination half-life is approximately 18–20 hours in healthy adults, allowing once-daily dosing.
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Rapidly hydrolyzed by nonspecific carboxylesterases in the blood and liver to an inactive metabolite (CNS7054); not significantly metabolized by CYP450 enzymes.
Hepatic metabolism primarily via CYP3A4, CYP1A2, and CYP2D6; also undergoes N-demethylation and glucuronidation. Active metabolites include norcyclobenzaprine.
Renal excretion of unchanged drug accounts for <1% of the dose; fecal excretion via biliary elimination is the primary route (≈90%), with the remainder as metabolites.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Highly protein-bound (>99%), primarily to albumin and α1-acid glycoprotein.
~93% bound to albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 1.5–2.0 L/kg, indicating extensive extravascular distribution.
~5 L/kg (range 3–7 L/kg). Clinical meaning: extensive tissue distribution, including central nervous system.
Oral bioavailability is approximately 30–40% due to first-pass metabolism.
Oral: 33–55% due to first-pass metabolism; lower for immediate-release compared to extended-release (same extent but slower absorption).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No specific dosing adjustment recommended; use caution in severe renal impairment due to potential accumulation.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate (Child-Pugh B): reduce dose to 2 mg twice daily. Severe (Child-Pugh C): not recommended.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated due to risk of toxicity (minimal data). Use with caution in mild to moderate impairment; consider lower starting dose.
Safety and efficacy not established. Use is not recommended in pediatric patients.
Not recommended for children under 15 years; safety and efficacy not established. For adolescents ≥15 years: same as adult dosing.
No specific dose adjustment recommended; monitor renal function and consider age-related decline in renal function.
Start with 5 mg once daily; increase slowly to a maximum of 10 mg three times daily over 2 weeks. Increased sensitivity; monitor for anticholinergic effects and sedation.
None
None
Respiratory depression and apnea,Hypotension and bradycardia,Risk of sedation and respiratory depression in elderly or debilitated patients,Potential for physical dependence and abuse,Need for continuous monitoring of vital signs
Serotonin syndrome risk, especially with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs),Sedation and impairment of motor skills; caution with driving or operating machinery,Anticholinergic effects (e.g., urinary retention, angle-closure glaucoma, constipation),Cardiovascular effects: tachycardia, QT prolongation, arrhythmias (especially in elderly or with pre-existing heart disease),Hepatic impairment: use with caution; reduced clearance in mild impairment, avoid in severe impairment,Withdrawal symptoms after abrupt discontinuation: dysphoria, anxiety, insomnia,Elderly patients: increased risk of falls, confusion, anticholinergic toxicity
Hypersensitivity to remimazolam or benzodiazepines,Acute narrow-angle glaucoma,Severe hepatic impairment (Child-Pugh class C)
Hypersensitivity to cyclobenzaprine or any component of the formulation,Concomitant use or within 14 days of MAO inhibitors (hypertensive crisis risk),Acute recovery phase after myocardial infarction,Arrhythmias, heart block, or conduction disturbances,Hyperthyroidism,Severe hepatic impairment
Avoid high-fat meals as they can significantly increase drug absorption and risk of adverse effects. Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 inhibition affecting metabolism. Limit caffeine intake as combination may exacerbate side effects like anxiety and palpitations.
Alcohol should be avoided due to additive CNS depression. Grapefruit juice may increase cyclobenzaprine levels (though data is limited, caution is advised). High-fat meals may delay absorption but not clinically significant. No specific dietary restrictions are required.
First trimester: Neural tube defects, cardiovascular malformations, and oral clefts reported in animal studies; human data limited. Second trimester: Increased risk of fetal growth restriction and preterm birth. Third trimester: Potential for neonatal respiratory depression, hypotonia, and withdrawal syndrome if used near term.
Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: Limited human data, but no structural anomalies reported. Second trimester: No specific adverse effects documented. Third trimester: Potential for neonatal withdrawal symptoms (e.g., jitteriness, respiratory depression) if used near term.
Excreted in breast milk; M/P ratio approximately 0.85. Not recommended due to risk of infant sedation, poor feeding, and potential long-term neurodevelopmental effects. Consider alternative therapies.
Cyclobenzaprine is excreted into breast milk in low amounts; the M/P ratio is unknown. Due to its anticholinergic effects, there is potential for adverse effects in the nursing infant (e.g., sedation, constipation). The American Academy of Pediatrics considers it compatible with breastfeeding, but caution is advised; alternatives may be preferred.
Increased clearance during pregnancy may necessitate dose adjustment; therapeutic drug monitoring recommended to maintain target trough concentrations. Postpartum, dose reduction may be required due to altered pharmacokinetics.
No specific dose adjustments are recommended during pregnancy. Pharmacokinetic parameters (e.g., clearance) are not significantly altered by pregnancy. Use the lowest effective dose for the shortest duration due to lack of safety data.
REVONTO is a proprietary formulation not recognized in standard medical literature. Verify with pharmacist for active ingredient(s) and dosing. If it contains naltrexone-bupropion combination (brand name Contrave), use with caution in patients with seizure history or eating disorders. Monitor blood pressure regularly due to possible hypertensive effects. Contraindicated with concomitant MAOIs or during abrupt opioid withdrawal.
Cyclobenzaprine is structurally related to tricyclic antidepressants and shares similar anticholinergic and sedative properties. Onset of action for muscle relaxation is typically 1 hour, but maximal effect may take several days. Avoid use in patients with hyperthyroidism, cardiac disease, or those on MAOIs. Not recommended for use longer than 2-3 weeks due to lack of evidence for chronic use. Caution in elderly due to anticholinergic effects and fall risk.
Take with a low-fat meal to reduce gastrointestinal side effects and improve tolerability.,Avoid alcoholic beverages as they may increase the risk of seizures and hepatotoxicity.,Report any signs of allergic reaction (rash, itching, swelling) or mood changes immediately.,Do not discontinue abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store at room temperature away from moisture and heat.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol or use other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication, as it may increase sedation.,Take this medication exactly as prescribed, usually 3 times a day. Do not take more or less than directed.,This medication is intended for short-term use (up to 2-3 weeks) for muscle spasm. Do not use it for longer without consulting your doctor.,If you experience dry mouth, try sucking on sugar-free candy or ice chips. If you have difficulty urinating or vision changes, contact your doctor.,Do not stop taking this medication abruptly without consulting your doctor, although withdrawal is uncommon with short-term use.
No interactions on record
"The combination of cyclobenzaprine and carbinoxamine results in additive central nervous system depression due to their shared anticholinergic and sedative properties. This can lead to excessive sedation, impaired cognitive and motor function, and increased risk of falls or accidents. Severe cases may result in respiratory depression, especially in elderly patients or those with preexisting conditions."
"Cyclobenzaprine, a centrally acting muscle relaxant with tricyclic antidepressant (TCA)-like structure, and Dezocine, an opioid partial agonist analgesic with mu-opioid receptor activity, both depress the central nervous system (CNS) and have additive serotonergic effects. Concomitant use increases the risk of excessive CNS depression, manifesting as sedation, respiratory depression, and impaired psychomotor function, as well as potential serotonin syndrome due to combined serotonergic activity. Clinically, patients may experience profound drowsiness, confusion, respiratory compromise, and in severe cases, coma or death from respiratory failure."
"Lumacaftor, a potent inducer of cytochrome P450 (CYP) 3A4, significantly reduces the systemic exposure of cyclobenzaprine, a CYP3A4 substrate. This results in decreased plasma concentrations of cyclobenzaprine, potentially leading to reduced therapeutic efficacy for muscle spasm relief. Patients may require dose adjustments or alternative therapies to maintain clinical benefit."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REVONTO vs CYCLOBENZAPRINE HYDROCHLORIDE, answered by our medical review team.
REVONTO is a Skeletal Muscle Relaxant that works by Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.. CYCLOBENZAPRINE HYDROCHLORIDE is a Skeletal Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REVONTO and CYCLOBENZAPRINE HYDROCHLORIDE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REVONTO is: 4 mg orally twice daily, with or without food.. The standard adult dose of CYCLOBENZAPRINE HYDROCHLORIDE is: Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REVONTO and CYCLOBENZAPRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REVONTO is classified as Category C. First trimester: Neural tube defects, cardiovascular malformations, and oral clefts reported in animal studies; human data limited. Second trimester: Increased risk of fetal growth. CYCLOBENZAPRINE HYDROCHLORIDE is classified as Category A/B. Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.